Lupus & antiphospholipid syndrome
Assessing the Sensitivity and the Clinical Impact of the 2023 American College of Rheumatology/ EULAR Classification Criteria in Obstetric Antiphospholid Syndrome: Findings From a Multicenter Italian Cohort With a Long‐Term Follow‐Up
Authors' conclusion
The 2023 ACR/EULAR classification criteria demonstrate low sensitivity (23%) in women with primary oAPS and fail to identify those at risk of future events.
Study context
- Population
- Women diagnosed with primary obstetric antiphospholipid syndrome (APS) (obstetric APS (oAPS)) by expert rheumatologists, 2006–2023, two Italian rheumatology centres
- Participants
- 122 women
- Exposure
- 2023 American College of Rheumatology (ACR)/EULAR vs 2006 Sydney classification criteria
- Outcome
- Sensitivity of the 2023 ACR/EULAR classification criteria for APS in primary oAPS
- Follow-up
- Baseline
Methodological detailsmulticentre, two Italian rheumatology centres
- Multicentre
- Two Italian rheumatology centres
Main finding
As reported in the abstract
Patients fulfilling classification criteria at baseline
Observational data: associations, not effects.
Further findings
Reasons for exclusion under 2023 ACR/EULAR criteria · baseline
- Insufficient clinical score due to isolated fetal losses
- 56.4%
- Insufficient laboratory score due to isolated IgM aPL positivity
- 4.3%
- Combination of both
- 5.3%
New obstetric events during follow-up · 5 years
- More than one-quarter of patients who became pregnant experienced new obstetric events; the majority did not fulfil the 2023 ACR/EULAR criteria
Original publication
Assessing the Sensitivity and the Clinical Impact of the 2023 American College of Rheumatology/ EULAR Classification Criteria in Obstetric Antiphospholid Syndrome: Findings From a Multicenter Italian Cohort With a Long‐Term Follow‐Up. Arthritis Care Res (Hoboken). Published 29 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →